CD4 and neoplasm: Specifically, Kaplan–Meier survival analysis revealed a significantly better survival of patients with high CD3+ (DFS, P=0.0014; OS, P=0.0031) and CD4+ (DFS, P=0.0101; OS, P=0.0106) signals in the tumor region, but not with biomarker in the IM.